comparemela.com
Home
Live Updates
Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease : comparemela.com
Sangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data Showing Tolerability and Sustained Elevated a-Gal A Enzyme Activity in Patients With Fabry Disease
Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across three dose cohorts in the five treated patients - In the first two dose cohorts, all four patients exhibited above
Related Keywords
Aaron Feingold
,
Rob Schott
,
Jaya Ganesh
,
Exchange Commission
,
Icahn School Of Medicine At Mount Sinai
,
Drug Administration
,
Head Of Development At Sangamo
,
European Medicines Agency
,
Nasdaq
,
Sangamo Therapeutics Inc
,
Events Presentations
,
Icahn School
,
Mount Sinai
,
Orphan Drug
,
Orphan Medicinal Product
,
European Medicines
,
Annual Report
,
Quarterly Report
,
Sangamo
,
Herapeutics
,
Nnounces
,
Pdated
,
Reliminary
,
Hase
,
Data
,
Showing
,
Tolerability
,
Sustained
,
Levated
,
Nzyme
,
Activity
,
Patients
,
Ith
,
Dabry
,
Disease
,
comparemela.com © 2020. All Rights Reserved.